Synairgen reports positive safety data for SNG001 in phase 2 COPD trial

This article was originally published here

Synairgen said that its antiviral therapy SNG001 has so far registered positive safety data in an ongoing phase 2 trial in patients with chronic obstructive pulmonary disease (COPD).

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply